We are driven to make a difference for patients and those who care for them.
At the heart of everything we do at Syros is our dedication to advancing medicines that provide a profound and durable benefit for patients with difficult-to-treat diseases.
We are pioneering a new field of medicine focused on controlling the expression of genes. The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it changes the function of a cell, leading to disease. Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has potential to create medicines that provide patients with a range of diseases the opportunity to live longer and enjoy a better quality of life.
We are currently advancing two programs in clinical trials: SY-1425 in defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and SY-1365 in patients with ovarian and breast cancers. In addition, we have multiple programs in earlier stages of research for additional cancers, as well as genetic diseases, for which there is a dire need for better medicines.
We invite you to learn more about our programs and our ongoing clinical trials, as well as to explore a select list of resources for these diseases.
Nancy Simonian, M.D.
Chief Executive Officer of Syros